Which Medicines Can Worsen Myasthenia Gravis? What Your Team Checks Before Any Prescription

The urgent care clinician has already typed the prescription. A urinary infection, a quick course of a fluoroquinolone antibiotic, done. Then the patient mentions, almost as an afterthought, that she has myasthenia gravis and her eyelids droop by late afternoon. The clinician pauses, deletes the order and starts again. That pause is the whole story of this article.

For most people, a prescription is a small transaction. For someone living with myasthenia gravis, it is a safety check, because a surprising number of ordinary drugs can interfere with the fragile signal between nerve and muscle. Knowing the medicines that worsen myasthenia gravis, and why they do, turns a vague worry into a specific question you can ask at any pharmacy counter or hospital bed.

This guide explains which classes carry real evidence of harm, which carry only case reports, what anesthesia teams plan for, and the warning signs that mean weakness is no longer a wait-and-see matter.

How myasthenia gravis works, and why one tablet can tip the balance

Every voluntary movement starts with a chemical handshake. A nerve ending releases acetylcholine, a messenger molecule, across a microscopic gap called the neuromuscular junction, and the muscle fires when enough of it lands on receptors on the muscle surface. In myasthenia gravis, the immune system makes antibodies that attack those receptors or the proteins that anchor them. Fewer working receptors means the handshake sometimes fails, and muscles tire with use.

Healthy junctions have a large safety margin: far more acetylcholine is released than the muscle strictly needs. Myasthenia gravis erodes that margin. A person may feel fine at rest and then struggle to chew by the end of a meal. The margin is also why medicines matter so much. A drug that slightly reduces acetylcholine release, or slightly blocks the receptor, barely registers in someone with a normal junction. In someone whose junction is already running close to the edge, the same drug can mean double vision, a nasal voice or trouble swallowing within hours.

Standard treatment works on both sides of the gap. Acetylcholinesterase inhibitors, drugs that slow the breakdown of acetylcholine, give each nerve impulse more messenger to work with. Immune-directed treatments such as corticosteroids, steroid-sparing immunosuppressants, intravenous immunoglobulin and plasma exchange reduce the antibody attack itself. The National Institute of Neurological Disorders and Stroke notes that the condition affects an estimated 14 to 20 people per 100,000, and that most antibodies target the acetylcholine receptor.

The practical upshot: the question is never simply “is this drug on a list.” It is “what does this drug do at the junction, how much margin does this person currently have, and is there an equally good alternative.”

Which medicines that worsen myasthenia gravis top the list? Antibiotics first

Antibiotics sit at the top of nearly every neurologist’s caution list, partly because they are prescribed so often and partly because the evidence is strongest.

Aminoglycosides, a class that includes gentamicin, tobramycin and amikacin, carry the oldest and clearest warnings. They reduce acetylcholine release from the nerve ending and can also blunt the muscle’s response to it. Case reports of sudden respiratory weakness after an aminoglycoside date back decades, and these drugs are typically reserved for infections where no reasonable alternative exists, with close monitoring of breathing.

Fluoroquinolones, including ciprofloxacin, levofloxacin and moxifloxacin, carry a boxed warning in the United States stating they may exacerbate muscle weakness in people with myasthenia gravis and should be avoided unless benefits clearly outweigh risks. The mechanism is thought to involve direct interference with the receptor and with acetylcholine release.

Macrolides such as azithromycin, erythromycin and clarithromycin are a step down in strength of evidence but still prompt caution; worsening has been reported, and prescribing information for several of them mentions myasthenia gravis. Telithromycin, a related drug, caused severe reactions and is no longer widely used.

Where does that leave an ordinary chest or urinary infection? Usually with penicillins, cephalosporins, or other classes that have no meaningful effect at the junction. Untreated infection is itself one of the most common triggers of a myasthenic flare, so avoiding antibiotics altogether is not the goal. The goal is the right antibiotic, chosen with the diagnosis in view.

If a hospital team does decide an aminoglycoside or fluoroquinolone is necessary, that decision is usually paired with a plan: where the person will be monitored, how often breathing will be checked, and what will happen if swallowing or speech changes.

Myasthenia gravis drugs to avoid in heart, blood pressure and rhythm care

Cardiology is the second area where prescribing intersects with myasthenia gravis, and the evidence here is more mixed than the antibiotic story.

Beta blockers, used for blood pressure, angina, heart failure and some rhythm problems, are the most frequently cited. Reports describe increased weakness after both oral tablets and eye drops used for glaucoma, which is a useful reminder that drops can be absorbed into the bloodstream. The effect appears to be modest for most people, and many patients with stable myasthenia gravis take beta blockers without trouble. Prescribers generally avoid starting one during an active flare and prefer alternatives when the indication allows.

Class I antiarrhythmics such as quinidine and procainamide, drugs that stabilize heart rhythm by altering sodium channels, have well-described junction effects and are usually avoided. Quinine, a chemical cousin of quinidine, matters too; it is a historical treatment for leg cramps and still appears in tonic water, a point many people are surprised to learn.

Calcium channel blockers have scattered case reports but little consistent evidence; most teams view them as low risk. Intravenous magnesium, given for certain heart rhythms and in obstetrics for pre-eclampsia, deserves its own warning. Magnesium competes with calcium at the nerve terminal and reduces acetylcholine release. Rapid worsening after intravenous magnesium is well documented, so it is used only when essential, with monitoring.

Statins, taken by millions to lower cholesterol, have been linked to worsening in a small number of case reports. Mainstream guidance does not advise people with myasthenia gravis to stop them; cardiovascular benefit is substantial and the junction risk appears low. A new or unusual weakness after starting one is worth reporting, not worth self-adjusting.

Across all of these, the decision sits with the prescribing clinician, who balances the heart risk against the muscle risk for that particular patient.

Which muscle relaxants should be avoided in patients with myasthenia gravis?

“Muscle relaxant” is one label covering two very different families of drugs, and the answer depends on which family you mean.

The first family is neuromuscular blocking agents, the injectable drugs anesthetists use to paralyze muscles during surgery and intubation. Non-depolarizing agents such as rocuronium, vecuronium and cisatracurium work by blocking the acetylcholine receptor directly, the very receptor myasthenia gravis has already depleted. People with the condition are markedly more sensitive to them: a standard amount produces deeper, longer paralysis. Succinylcholine, the depolarizing agent, behaves the opposite way; a damaged receptor pool makes the drug less effective and its action harder to predict. Neither is strictly forbidden, but both require an anesthesia team that knows the diagnosis and adjusts its approach, often using the smallest effective amount, nerve monitoring and a reversal agent at the end.

The second family is oral muscle relaxants prescribed for back spasm or spasticity: cyclobenzaprine, baclofen, tizanidine, methocarbamol and dantrolene. These act mainly on the brain or spinal cord rather than at the junction. Their concern is indirect; they cause drowsiness, reduce respiratory drive and can mask early signs that breathing muscles are tiring. Dantrolene acts inside the muscle fiber itself and is generally avoided. Benzodiazepines, sometimes used as relaxants, share the sedation and breathing concern.

Botulinum toxin injections belong in this conversation as well, whether for cosmetic use, migraine or spasticity. The toxin works precisely by blocking acetylcholine release, and spread beyond the injection site can unmask or worsen myasthenia gravis. Most neurologists advise against it, or permit it only after a detailed risk discussion.

If a muscle relaxant is being considered for pain, the usual route is to ask whether physical therapy, heat, or a non-sedating approach could do the same job first.

Anesthesia and surgery: what the team actually checks before an operation

Surgery is where the medication question becomes concrete, because an operation bundles several risks together: anesthetic drugs, stress, possible infection, and a period of fasting that disrupts the usual timing of acetylcholinesterase inhibitors.

A typical pre-operative review covers four areas. First, how well controlled the condition is right now. Elective surgery is usually scheduled when weakness is stable, and some teams work with the neurologist beforehand to optimize treatment, occasionally with intravenous immunoglobulin or plasma exchange for people with significant bulbar or breathing involvement.

Second, the anesthetic plan. The team notes any prior reactions to anesthesia, discusses whether a regional or local technique could avoid neuromuscular blockers entirely, and plans for reduced sensitivity to succinylcholine or heightened sensitivity to non-depolarizing agents. A reversal agent such as sugammadex, which binds and inactivates rocuronium and vecuronium, is often part of the plan for the end of the procedure.

Third, the medication timeline. Teams decide with the patient whether the morning dose of the usual myasthenia medicine is taken, when it restarts after surgery, and how it will be given if swallowing is temporarily unsafe. Corticosteroids taken long term require a plan for stress coverage, because the body cannot ramp up its own cortisol.

Fourth, post-operative monitoring. Breathing capacity may be measured before and after, and people with more severe disease may recover in a higher-dependency area where respiratory weakness can be caught early. Pain relief is planned with the awareness that opioids suppress breathing; they are used, but carefully, alongside non-opioid options where possible.

Thymectomy, surgical removal of the thymus gland, is a specific case. The Mayo Clinic notes that the thymus is involved in some forms of the disease and that removal is considered for certain patients; the same anesthetic principles apply.

None of this means surgery is off limits. It means the operating team expects the diagnosis to be on the front page of the chart.

Medicines that can cause new myasthenia gravis: penicillamine, checkpoint inhibitors and others

A separate and smaller group of drugs does something different from worsening existing weakness. They appear to trigger the autoimmune process itself in people who had no prior diagnosis.

Penicillamine, used for Wilson’s disease and historically for rheumatoid arthritis, is the classic example. A proportion of people taking it develop acetylcholine receptor antibodies and symptoms indistinguishable from spontaneous myasthenia gravis. The picture usually settles over the months after the drug is withdrawn under supervision, which is one reason it is recognized as drug-induced rather than drug-unmasked.

Immune checkpoint inhibitors are the modern concern. These cancer immunotherapies, including pembrolizumab, nivolumab and ipilimumab, release the brakes on the immune system so it can attack tumors. The same release can produce autoimmune side effects, and myasthenia gravis is among the most serious of the neurological ones. It can appear within weeks of the first infusions, is sometimes accompanied by inflammation of the heart muscle (myocarditis) and skeletal muscle (myositis), and can progress rapidly to breathing failure. Oncology teams screen for new weakness, drooping eyelids, double vision or shortness of breath at every visit, and treat early with high-dose steroids and often immunoglobulin or plasma exchange. People with pre-existing myasthenia gravis who need these drugs face a careful benefit-risk discussion; the condition does not automatically rule immunotherapy out, but it changes the monitoring.

Interferon alpha, chloroquine and hydroxychloroquine have also been linked to new or worsened myasthenia gravis in case series. Hydroxychloroquine is widely used for lupus and rheumatoid arthritis, so this one comes up often; the risk appears low, and rheumatologists and neurologists usually make a shared decision rather than a blanket ban.

The pattern across this group is the same: symptoms that begin after a new drug deserve a prompt conversation, not a quiet wait to see whether they pass.

Medicines that worsen myasthenia gravis at a glance: a summary table

Lists of risky drugs circulate widely, and many lump everything together with the same alarm. The table below separates classes by how strong the evidence is and what the usual clinical approach looks like. It is a guide to the conversation with your team, not a substitute for it.

Medicine class (examples)	Main mechanism at the junction	Strength of evidence	Usual clinical approach
Aminoglycoside antibiotics (gentamicin, tobramycin)	Reduced acetylcholine release, blunted muscle response	Strong	Avoid unless no alternative; monitor breathing
Fluoroquinolones (ciprofloxacin, levofloxacin)	Receptor and release interference	Strong; boxed warning	Avoid where possible
Macrolides (azithromycin, erythromycin)	Release interference	Moderate	Use with caution; alternatives preferred
Intravenous magnesium	Competes with calcium, cuts release	Strong	Only when essential; monitored
Botulinum toxin	Blocks release directly	Strong	Generally avoided
Neuromuscular blockers (rocuronium, succinylcholine)	Receptor blockade or altered response	Strong	Used by informed anesthesia team with adjustments
Beta blockers	Uncertain; weakness reported	Moderate	Caution, especially during flares
Class I antiarrhythmics, quinine	Membrane and junction effects	Moderate to strong	Usually avoided
Penicillamine	Induces autoimmune disease	Strong	Avoid; withdraw if symptoms appear
Immune checkpoint inhibitors	Immune activation	Strong	Benefit-risk decision with close monitoring
Statins	Unclear	Weak; case reports	Continue; report new weakness
Hydroxychloroquine, chloroquine	Unclear	Weak to moderate	Shared decision
Opioids, benzodiazepines, sedating relaxants	Breathing suppression, not junction	Indirect	Use lowest effective approach; monitor

Two things stand out. The classes with the strongest evidence tend to be drugs given in hospital, where monitoring is possible. The classes people encounter in daily life carry weaker or indirect evidence, which is reassuring but still a reason to keep the diagnosis visible on every prescription.

What triggers a myasthenia gravis flare-up besides medicines? Myasthenia gravis flare up triggers explained

Medicines are only one lever. People often blame a tablet for a worsening that had several contributing causes, so it helps to know the full roster.

Infection is the most common trigger. The NHS and Mayo Clinic both list it prominently, and the mechanism is twofold: fever and inflammatory signals seem to worsen transmission at the junction, and the body’s energy reserves are diverted. Even a mild cold can show up as heavier eyelids and slurred speech a day or two later.

Physical stress of any kind, including surgery, injury and poor sleep, sits close behind. Emotional stress is reported by many patients, though it is harder to measure. Heat is a well-recognized factor: warm weather, hot showers and saunas can all increase weakness, because higher temperature speeds the breakdown of acetylcholine.

Hormonal shifts matter. Some people notice changes around menstruation, and pregnancy and the weeks after birth are a recognized period of instability, which is why obstetric and neurology teams usually plan together. Thyroid disease, which is more common in people with myasthenia gravis, can worsen weakness whether the gland is overactive or underactive.

Missing or mistiming the usual acetylcholinesterase inhibitor is a trigger people sometimes overlook, especially during travel or illness with vomiting. Reducing immunosuppressive treatment too quickly is another, and it is one reason changes are made gradually under supervision rather than on a patient’s own initiative.

Finally, there is the overlap effect. A fluoroquinolone prescribed for a urinary infection during a heatwave in someone who slept poorly stacks three triggers at once. Teasing out which one tipped the balance is often impossible, and in practice the response is the same: treat the infection with a safer antibiotic, rest, cool down, and let the neurology team know early.

Who is usually told to avoid these medicines, and who is asked to wait

Not everyone with myasthenia gravis faces the same risk from the same drug, and prescribing decisions reflect that.

People with generalized disease, meaning weakness beyond the eye muscles, and especially those with bulbar involvement (difficulty chewing, swallowing or speaking) or any history of breathing weakness, are treated with the most caution. For this group, even a moderate-evidence drug such as a macrolide is usually swapped for an alternative, and strong-evidence drugs are reserved for genuine necessity with hospital monitoring.

People with purely ocular myasthenia gravis, where only eyelid and eye movement muscles are affected, have more margin. Many take medicines from the caution list without incident. Prescribers still note the diagnosis, because a proportion of ocular cases progress to generalized disease, typically within the first couple of years according to the National Institute of Neurological Disorders and Stroke.

People in remission, whether spontaneous or on treatment, are often managed similarly to those with ocular disease, with the diagnosis flagged and a plan to report any new weakness.

Who is asked to wait? Elective procedures that require neuromuscular blockers, botulinum toxin injections for cosmetic reasons, and non-urgent prescriptions from the caution list are commonly postponed when someone is in a flare or has recently changed immune treatment. Pregnancy and the postpartum weeks are another period when teams prefer to defer optional exposures. Someone newly diagnosed, whose treatment has not yet stabilized, is usually asked to hold off on anything non-essential until the picture is clearer.

The principle underlying all of this is the safety margin described earlier. The less margin a person has today, the more carefully each new exposure is weighed, and that assessment belongs to the neurologist and prescribing clinician working together.

What the first days and weeks look like after a drug-related worsening

Suppose the pause in the opening scene never happened and the fluoroquinolone was taken. What tends to follow?

Worsening from a junction-active drug usually appears quickly, within hours to a few days of the first doses, rather than creeping in over months. The early signs mirror the person’s usual pattern: eyelids drooping earlier in the day, double vision, a voice that goes nasal or quiet with conversation, food catching on the way down. Breathing involvement is the sign that changes everything and is covered in the red-flag section below.

The first step is almost always to stop the suspect drug, which the prescriber does by replacing it with a safer alternative rather than leaving an infection untreated. Many people recover their baseline within days of stopping as the drug clears, although the exact timing depends on the drug’s half-life and on whether infection or another trigger is still active.

If weakness is significant, the neurology team may temporarily adjust the acetylcholinesterase inhibitor or add a short-term immune treatment. Intravenous immunoglobulin and plasma exchange, both described by the NHS as options for sudden severe worsening, typically begin to help within days and are used as a bridge while longer-acting immune treatments take effect. A hospital stay with breathing monitoring is common for anyone with swallowing or respiratory signs.

Drug-induced disease, as with penicillamine, follows a slower arc; improvement after withdrawal is measured in months rather than days, with antibody levels followed over time.

In the weeks that follow, the useful work is documentation. The reaction goes into the medical record as an adverse drug event, the pharmacy flags the class, and the person adds it to whatever alert card or phone note they carry. That record is what prevents the same conversation from being needed twice.

What disease mimics myasthenia gravis? Diseases that mimic myasthenia gravis and why it matters for prescribing

Drug safety lists assume the diagnosis is right. A handful of conditions look enough like myasthenia gravis that they are sometimes mistaken for it, and some carry their own medication cautions.

Lambert-Eaton myasthenic syndrome is the closest relative. It is also autoimmune, but the antibodies attack calcium channels on the nerve ending, so less acetylcholine is released in the first place. Weakness tends to affect the legs more than the eyes and may briefly improve with repeated effort, the reverse of myasthenia gravis. It is frequently associated with small-cell lung cancer, which changes the entire investigation. Many of the same drugs, including magnesium and aminoglycosides, worsen it.

Botulism produces descending weakness with drooping eyelids and swallowing difficulty because the toxin blocks acetylcholine release. It is an emergency and is treated with antitoxin rather than myasthenia medicines.

Thyroid eye disease causes double vision and eyelid changes through inflammation of the eye muscles rather than a junction problem; the two conditions can also coexist. Chronic progressive external ophthalmoplegia, a mitochondrial disorder, causes slowly progressive drooping and limited eye movement without the fluctuation typical of myasthenia gravis.

Motor neuron disease, stroke affecting the brainstem, multiple sclerosis and Guillain-Barré syndrome (including its Miller Fisher variant, which targets eye movements) all appear on the list of considerations, usually separated by reflex findings, sensory symptoms, imaging and antibody tests.

Why does this belong in an article about medicines? Because the right drug caution depends on the right diagnosis. Someone labeled with myasthenia gravis who actually has Lambert-Eaton syndrome may be missing a cancer search; someone with thyroid eye disease is being denied beta blockers for no reason. Confirming the diagnosis with antibody testing and electrical studies, as the Mayo Clinic describes, is the foundation on which every prescribing decision rests.

What people often get wrong about medicines and myasthenia gravis

Myth one: every drug on the list is forbidden. In reality the lists mix strong evidence, isolated case reports and theoretical concern. Treating a statin like an aminoglycoside leads people to stop heart protection they need. The honest position is graded: avoid the strong-evidence classes where alternatives exist, use caution with the moderate ones, and simply stay observant with the weak ones.

Myth two: a medicine is safe because it was taken before without trouble. Safety margin changes. A beta blocker tolerated for years may feel different during an infection or a flare. Past tolerance is useful information, not a guarantee.

Myth three: over-the-counter means irrelevant. Quinine in tonic water, magnesium supplements marketed for sleep or cramps, and sedating antihistamines in cold remedies all have a theoretical or reported effect. Oral magnesium is far less concerning than the intravenous form, since absorption is limited, but large supplemental amounts are still worth mentioning to the team. Pharmacists are an underused resource here; they see the full list.

Myth four: vaccines are dangerous. Infection is a leading flare trigger, and inactivated vaccines, including influenza, pneumococcal and the standard COVID-19 vaccines, are generally encouraged. Live vaccines are the exception for people on significant immunosuppression, and that is a question for the treating team rather than a reason to skip immunization.

Myth five: steroids only help. Corticosteroids are a mainstay of immune treatment, yet an early, temporary dip in strength after starting them is a recognized effect described in standard neurology references, which is why initiation is often supervised closely. Knowing this in advance stops a frightening week from feeling like treatment failure.

Myth six: stopping a suspect drug yourself is the safe choice. Sudden withdrawal of a beta blocker or an antiarrhythmic carries its own risks. The safe choice is a same-day phone call so the prescriber can substitute rather than abandon.

Questions to ask your care team before any new prescription

A short, specific set of questions does more than a memorized drug list. These are the ones neurologists and pharmacists say they wish patients asked more often.

• Does this medicine have any known effect at the neuromuscular junction, and how strong is the evidence?
• Is there an equally effective alternative from a class that does not appear on the caution lists?
• If this drug is necessary, what signs should I watch for, and over what time window would a reaction typically appear?
• Should my neurologist be told before I start, or is this something you can decide together today?
• How does this interact with my current myasthenia medicines, including any immunosuppressant?
• If I am having a procedure, will the anesthesia team know my diagnosis in advance, and can we avoid neuromuscular blockers?
• What should I do with my usual medicines on the day of surgery, and how will they be given if I cannot swallow afterward?
• Are any of my eye drops, supplements or over-the-counter products a concern?
• Which vaccines do you recommend for me, and are any live vaccines off the table because of my treatment?
• Is my diagnosis confirmed by antibody testing or electrical studies, so that the cautions actually apply to me?

It also helps to carry a one-line summary: the diagnosis, the subtype (ocular or generalized), current treatments, and any previous drug reactions. Many people keep this as a phone note or wallet card. Emergency clinicians have minutes, not hours, and that line can be the difference between a reconsidered prescription and a preventable crisis.

Finally, ask who to call outside office hours. Drug reactions do not keep business hours, and knowing the route to urgent advice in advance removes hesitation when it matters.

When to call your doctor: red-flag signs with myasthenia gravis

Most medication-related worsening is mild and reversible once the drug is stopped. The reason for vigilance is the small proportion that is not. Myasthenic crisis, the point at which breathing or swallowing muscles weaken enough to need urgent support, affects an estimated 15% to 20% of people with the condition at some point, according to the Cleveland Clinic, and it can develop within hours.

Call emergency services or go to the nearest emergency department immediately if you notice any of the following, particularly after starting a new medicine:

• Shortness of breath at rest, difficulty taking a deep breath, or needing to sit upright to breathe
• Inability to swallow saliva, choking on liquids, or a wet, gurgling voice
• Speech that becomes too weak or slurred to be understood
• Weakness that is rapidly worsening over hours rather than fluctuating through the day
• Confusion, drowsiness or a bluish tinge to the lips, which can signal low oxygen
• Chest pain or palpitations alongside new weakness, especially during cancer immunotherapy

Contact your neurology team or prescribing clinician the same day, rather than waiting for a scheduled visit, if you have milder but definite worsening after a new drug: earlier eyelid drooping, new double vision, fatigue with chewing, or a voice that tires quickly. Describe the drug, when you started it and when symptoms changed.

Do not stop a prescribed heart or blood pressure medicine on your own in response to these signs; tell the prescriber and let them substitute. Do not take extra doses of your myasthenia medicine to compensate, since overtreatment can itself cause weakness that looks similar to crisis.

If in doubt, choose the earlier call. Clinicians would rather reassure ten people than miss one whose breathing is quietly failing.

Frequently asked questions

What drugs should you avoid with myasthenia gravis?

The classes most consistently avoided are aminoglycoside and fluoroquinolone antibiotics, intravenous magnesium, botulinum toxin, penicillamine, class I antiarrhythmics such as quinidine, and quinine. Macrolide antibiotics and beta blockers are used with caution. Many others on circulating lists rest on isolated case reports. The prescriber weighs each case; avoidance is about choosing alternatives, not refusing treatment.

What triggers a myasthenia gravis flare-up?

Infection is the leading trigger, followed by surgery, physical or emotional stress, poor sleep, heat, thyroid imbalance, pregnancy and the weeks after birth, and missed or mistimed myasthenia medicines. Certain drugs, especially particular antibiotics and anesthetic agents, add to that list. Flares often come from several triggers stacking together rather than a single cause.

What disease mimics myasthenia gravis?

Lambert-Eaton myasthenic syndrome is the closest mimic; it is also autoimmune but attacks calcium channels on the nerve and is often linked to lung cancer. Botulism, thyroid eye disease, chronic progressive external ophthalmoplegia, Guillain-Barré syndrome, motor neuron disease, multiple sclerosis and brainstem stroke are also considered. Antibody tests and electrical studies usually separate them.

Which muscle relaxants should be avoided in patients with myasthenia gravis?

Injectable neuromuscular blockers used in anesthesia, such as rocuronium and succinylcholine, require specialist adjustment rather than routine use. Oral relaxants like cyclobenzaprine, baclofen and tizanidine mainly cause sedation that can mask breathing weakness; dantrolene is generally avoided. Botulinum toxin blocks acetylcholine release directly and is usually avoided. Discuss any relaxant with your neurologist first.

Are antibiotics safe with myasthenia gravis?

Most are. Penicillins, cephalosporins and several other classes have no meaningful effect at the neuromuscular junction and are used routinely. The concern centers on aminoglycosides, fluoroquinolones and, to a lesser degree, macrolides. Because untreated infection itself triggers flares, the usual answer is a safer antibiotic chosen with the diagnosis in view, not avoiding antibiotics.

Can I take a beta blocker if I have myasthenia gravis?

Many people do without problems, but beta blockers appear on caution lists because increased weakness has been reported, including from glaucoma eye drops. Prescribers often avoid starting one during a flare and may prefer alternatives when the heart indication allows. Never stop a beta blocker on your own; sudden withdrawal carries its own risks.

Does magnesium make myasthenia gravis worse?

Intravenous magnesium can cause rapid, serious worsening because it competes with calcium at the nerve ending and reduces acetylcholine release, so it is used only when essential and with monitoring. Oral supplements are absorbed far less and are much lower risk, though large amounts are still worth mentioning to your team. Dietary magnesium in food is not a concern.

Can cancer immunotherapy cause myasthenia gravis?

Yes. Immune checkpoint inhibitors such as pembrolizumab, nivolumab and ipilimumab can trigger new myasthenia gravis, usually within the first weeks of treatment, sometimes alongside heart or skeletal muscle inflammation. It is uncommon but can be severe. Oncology teams watch for drooping eyelids, double vision, swallowing trouble or breathlessness and treat early.

Is it safe to have surgery and anesthesia with myasthenia gravis?

Surgery is possible with planning. Anesthesia teams who know the diagnosis use regional techniques where feasible, adjust or avoid neuromuscular blockers, plan reversal agents, time the usual myasthenia medicines around fasting and monitor breathing afterward. Elective operations are generally scheduled when the condition is stable, sometimes after neurology optimizes treatment beforehand.

Should I avoid vaccines because I have myasthenia gravis?

Generally no. Infection is a leading flare trigger, so inactivated vaccines including influenza, pneumococcal and COVID-19 vaccines are usually encouraged. The main exception is live vaccines in people on significant immunosuppressive treatment, which need a specific decision from the treating team. Ask your neurologist which vaccines fit your current treatment.

References

• Myasthenia Gravis – National Institute of Neurological Disorders and Stroke (NIH)
• Myasthenia gravis – Treatment – NHS
• Myasthenia Gravis (MG) – Cleveland Clinic
• Myasthenia Gravis – MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.